India Glycols Q1 FY27 Earnings Call — Analysis (NSE: INDIAGLYCO)
India Glycols kicks off FY27 with record EBITDA, IMFL volumes doubling, and demerger NCLT approval, while setting ambitious segment-wise aspirations for the next 4–5 years.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Consolidated net revenue ₹1,130 Cr ( +9% YoY ) . New guidance — FY27 ennature bio pharma segment rev… ₹150 Cr plus . New story: Premiumization and IMFL volume surge .
Results
Consolidated net revenue ₹1,130 Cr (+9% YoY), EBITDA ₹170 Cr (+13% YoY), EBITDA margin 15.0% (+70 bps YoY), PAT ₹96.83 Cr (+32% YoY); IMFL volumes surged 55% YoY to 1.4 mn cases, Prestige & Above doubled to 0.5 mn cases.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated net revenue | ₹1,130 Cr | +9% | yoy · Q1FY27 |
| Consolidated EBITDA | ₹170 Cr | +13% | yoy · Q1FY27 |
| Consolidated EBITDA margin | 15.0% | +70 bps | yoy · Q1FY27 · vs 14.3% in Q1FY26 |
| PAT | ₹96.83 Cr | +32% | yoy · Q1FY27 |
| Finance cost | ₹25 Cr | -44% | yoy · Q1FY27 · down from ₹45 Cr in Q1FY26 |
| IGL Spirits segment net revenue | ₹694 Cr | yoy · Q1FY27 · segment-level, no explicit YoY% stated | |
| IGL Spirits segment EBITDA | ₹120 Cr | +17% | yoy · Q1FY27 · as per Anand Singhal |
| IGL Spirits segment EBITDA margin | 17.3% | +260 bps | yoy · Q1FY27 · vs 14.7% in Q1FY26 |
| Chemicals segment net revenue | ₹345 Cr | +24% | yoy · Q1FY27 |
| Chemicals segment EBITDA | ₹40 Cr | +12% | yoy · Q1FY27 |
| Chemicals segment EBITDA margin | 11.6% | yoy · Q1FY27 · no explicit YoY delta given | |
| Ennature Bio Pharma net revenue | ₹90 Cr | +53% | yoy · Q1FY27 |
| Ennature Bio Pharma EBITDA | ₹10 Cr | +~100% | yoy · Q1FY27 |
| Ennature Bio Pharma EBITDA margin | 11.1% | yoy · Q1FY27 | |
| IMFL volume | 1.4 million cases | +55% | yoy · Q1FY27 |
| IMFL Prestige & Above volume | 0.5 million cases | +doubled | yoy · Q1FY27 |
Guidance
IGL Spirits guided EBITDA in excess of ₹500 Cr for FY27 with IMFL volume doubling; management shared aspirational segment targets for FY30-32 of ~₹1,000 Cr spirits EBITDA, ~₹400 Cr chemicals EBITDA, and ~₹130-150 Cr Bio Pharma EBITDA.
What management committed to
- IGL Spirits will deliver an EBITDA in excess of ₹500 Cr in [FY27]. — in excess of INR500 crores, FY27
- IMFL volumes will double in [FY27] from [FY26 levels (~3.4 mn cases)]. — doubling, FY27
- [IGL Spirits] will become a debt-free company from FY28 onwards. — FY28
- [IGL Spirits] will achieve EBITDA in excess of ₹1,000 Cr in the next four to five years. — in excess of INR1,000 crores, next four to five years
- [Chemicals segment] will reach revenue of approximately ₹2,500 Cr and EBITDA of about ₹400 Cr in the next four to five years. — INR2,500 crores revenue, INR400 crores EBITDA, next four to five years
- [Ennature Bio Pharma] revenue will exceed ₹150 Cr in [FY27]. — INR150 crores plus, FY27
- [Ennature Bio Pharma] will achieve revenue of ₹600-700 Cr and EBITDA of ₹130-150 Cr in the next four to five years. — INR600-700 crores revenue, INR130-150 crores EBITDA, next four to five years
- [Ennature Bio Pharma] gross margins will be closer to about 30% by 2030. — closer to about 30%, FY30
Key themes
Premiumization, demerger, and bio-chemicals growth drive aspirations
How the narrative shifted
- Premiumization and IMFL volume surge: India Glycols is aggressively moving up the value chain in spirits through launches in deluxe whiskey, semi-premium vodka, and white spirits, while 55% IMFL volume growth and doubling of Prestige & Above cases signals early success of premiumization.
- Demerger unlocking shareholder value: The NCLT-approved demerger will create three focused entities, allowing clearer investment theses for consumer and B2B technology businesses, and management expects better investor clarity and potential partnerships.
- Bio-chemicals innovation-led growth: India Glycols positions itself as the world’s largest bio-based specialty chemicals supplier, leveraging innovation in process chemistry and collaborations with global majors (BASF, L’Oréal, Unilever) to drive future specialty chemical revenue.
- Bio Pharma nicotine and nutraceutical expansion: Ennature Bio Pharma delivered a breakout quarter, driven by nicotine capacity expansion and customer conversions in Europe; management plans to build a ₹600-700 Cr revenue franchise with 30% gross margins by 2030.
- Sustained margin expansion: Management highlights consistent EBITDA margin improvement from 9.6% in FY22 to 15.5% in FY26, driven by cost management, feedstock optimisation, and a shift toward value-added products across all segments.
- Geopolitical tailwinds and headwinds: The Mideast war created a mixed impact: crude spike improved competitiveness of bio-based EO versus petro-alternatives, but freight volatility and raw material shortages hurt oil & gas chemical supplies and export logistics.
- Debt-free trajectory by FY28: Strong cash flows and debt reduction have halved finance costs, with explicit target to make the spirits business debt-free from FY28, supporting higher RoE and reinvestment capacity.
Operational commentary
- IMFL volume surged 55% YoY to 1.4 mn cases; Prestige & Above segment doubled to 0.5 mn cases, driven by new brand launches and deeper penetration in UP, Uttarakhand, Delhi.
- Strategic distribution and marketing partnership with Amrut for premium whiskies and single malts, targeting doubling of Amrut whiskey volumes and >10,000 cases of single malt in operating states.
- New IMFL launches planned in deluxe whiskey, semi-premium vodka, and white spirits to accelerate premiumization and lift margins.
- Defence canteen channel approvals secured for 3 brands, with a fourth in pipeline, enabling all-India footprint for the spirits business.
- NCLT approved demerger scheme on 17 July 2026; effective date pending; separate entities will house chemicals, spirits+biofuel, and bio pharma, unlocking focus and investor clarity.
- Ennature Bio Pharma delivered best-ever quarter with nicotine sales doubling QoQ, customer conversions in Europe, and launch of crude processing capacity at Kashipur; branded nutraceutical portfolio strengthening.
- Chemicals innovation: first-ever bio-based amines and carbon-smart ethoxylates/glycols launched; collaborative partnerships with BASF, L'Oréal, Unilever, Mibelle driving specialty chemical pipeline.
- Captive high-quality ENA and ethanol capacity provide cost advantage and margin protection in both potable spirits and bio-fuel segments.
- Debt reduction continued, finance cost halved YoY; balance sheet improved with lower debt-to-equity.
Analyst Q&A
Q. How much is the royalty that will be paid to Amrut for the distribution partnership?
That is something which we cannot disclose.
Q. Explanation for the sequential EBITDA growth volatility (negative 5.16% in March quarter, then only 1.69% in June quarter)
We will reply by mail — send us an email and we will provide the details.
Research and educational content only. Not investment advice.